Inicio > Ultimas Publicaciones de la Revista > Farmacología > Nuevas vías terapéuticas en el asma bronquial > Página 4

Nuevas vías terapéuticas en el asma bronquial

10. Reddel HK, Taylor DR, Bateman ED.; American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. AmJ Respir Crit CareMed 2009;180(1):59–99

11. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006;368(9537):804–13

12. Lötvall J, Akdis CA, Bacharier LB. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011;127(2):355–60

13. Matera MG, Page CP, Cazzola M. Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol Sci 2011;32(8):495–506

14. Park HW, Yang MS, Park CS. Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response. Allergy 2009;64(5):778–83

15. Peters SP, Kunselman SJ, Icitovic N, et al; National Heart, Lung, and Blood Institute Asthma Clinical Research Network. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010;363(18):1715–1726

16. Deshpande DA, Wang WC, McIlmoyle EL, et al. Bitter taste receptors on airway smooth muscle bronchodilate by localized calcium signaling and reverse obstruction. Nat Med 2010;16(11):1299–1304

17. Barnes PJ. Triple inhalers for obstructive airways disease:will they be useful? Expert Rev Respir Med 2011;5(3):297–300

18. Barnes PJ. Glucocorticosteroids: current and future directions. Br J Pharmacol 2011;163(1):29–43

19. Barnes PJ. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol 2006;148(3):245–54

20. Schäcke H, Schottelius A, Döcke WD. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci U S A 2004;101(1):227–32

21. Barnes PJ. Histone deacetylase-2 and airway disease. Ther Adv Respir Dis 2009;3(5):235–43

22. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 2008;8(3):183–92

23. Hamid Q, Tulic M. Immunobiology of asthma. Annu Rev Physiol 2009;71:489–507

24. Barnes PJ. Pathophysiology of allergic inflammation. Immunol Rev 2011;242(1):31–50

25. Rosenwasser LJ, Meng J. Anti-CD23. Clin Rev Allergy Immunol 2005;29(1):61–72

26. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet 2009;373(9678):1905–17

27. Barnes PJ. New molecular targets for the treatment of neutrophilic diseases. J Allergy Clin Immunol 2007;119(5):1055–62

28. Rosenwasser LJ, Meng J. Anti-CD23. Clin Rev Allergy Immunol 2005;29(1):61–72